Mar 16, 2021

Starpharma (ASX:SPL) reports DEP HER2-lutetium shows potent anticancer effect

Starpharma (ASX:SPL) reports DEP HER2-lutetium shows potent anticancer effect

Finance News Network reported that Starpharma's second radiopharmaceutical candidate, DEP HER2-lutetium, achieved potent and durable anticancer activity, with complete tumour regression, outperforming Herceptin labelled with lutetium, in a breast cancer model. Read more here

 This contains certain forward-looking statements.